Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016560 · ClinicalTrials.gov registry record · Phase 2
Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects
A Phase 2 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 383
- Enrollment target
NCT02016560: Completed Phase 2 study, sponsored by Avid Radiopharmaceuticals.
NCT02016560 is a Phase 2 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 383 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (188% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02016560, a Phase 2 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 383 participants
- Enrollment target
Study Summary
A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).
Primary Outcome
Confirm the relationship between neocortical flortaucipir uptake and the subsequent rate of cognitive decline at longitudinal follow up that was observed in the Exploratory Phase of the study. Patients were assigned to groups by majority classification of the flortaucipir positron emission tomography (PET) scan by five independent imaging physicians. Clinically meaningful cognitive and functional deterioration was defined as a 1 point or greater worsening on clinical dementia rating - sum of box
Interventions
- DRUG Flortaucipir F18
- PROCEDURE Brain PET Scan
- DRUG florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-07-28 |
| Phase | Phase 2 |
What the finished NCT02016560 record still lists
NCT02016560 is an interventional study that assigns participants to a tested intervention. The registered 383 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (188% higher).
The record links to 0 conditions, and to 3 interventions - of which Flortaucipir F18 is the first listed.
NCT02016560 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02016560 about?
NCT02016560 is a clinical study titled "Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects". A Phase 2/3 cross-sectional and longitudinal observational study evaluating imaging characteristics of flortaucipir in control subjects and patients with clinically defined MCI and AD dementia (AD).
What is the current status of trial NCT02016560?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 383 participants. The study started on 2013-12. Estimated completion is 2017-07-28.
What interventions are being tested in trial NCT02016560?
The interventions under investigation include: Flortaucipir F18 (DRUG), Brain PET Scan (PROCEDURE), florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT02016560?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02016560's enrollment target sits among peer trials
383 111th of 2000 higher than 1,890 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06056830 · 383 participants · Phase 3
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
- NCT06277661 · 384 participants · NA
The Mom and Infant Outcomes (MOMI) Study
- NCT06372964 · 384 participants · Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- NCT06501040 · 384 participants · NA
Increasing Knowledge and Interest in Cancer Clinical Trials
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia